tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c)
PremiumThe FlyAllogene Therapeutics reports Q3 EPS (19c), consensus (23c)
1M ago
Allogene Therapeutics downgraded to Underweight from Neutral at JPMorgan
Premium
The Fly
Allogene Therapeutics downgraded to Underweight from Neutral at JPMorgan
2M ago
Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
Premium
Company Announcements
Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
3M ago
Allogene Therapeutics Advances in CAR T Cell Therapy
PremiumCompany AnnouncementsAllogene Therapeutics Advances in CAR T Cell Therapy
4M ago
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
Premium
The Fly
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
4M ago
Allogene Therapeutics options imply 16.7% move in share price post-earnings
Premium
The Fly
Allogene Therapeutics options imply 16.7% move in share price post-earnings
4M ago
Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan
PremiumThe FlyAllogene Therapeutics downgraded to Neutral from Overweight at JPMorgan
5M ago
Allogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
Premium
The Fly
Allogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
5M ago
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
Premium
Company Announcements
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100